Cargando…

Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine

BACKGROUND: Ukraine is among ten countries with the highest burden of multidrug- resistant TB (MDR-TB) worldwide. Treatment success rates for MDR-TB in Ukraine remain below global success rates as reported by the World Health Organization. Few studies have evaluated predictors of poor MDR-TB outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Aibana, Omowunmi, Bachmaha, Mariya, Krasiuk, Viatcheslav, Rybak, Natasha, Flanigan, Timothy P., Petrenko, Vasyl, Murray, Megan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294867/
https://www.ncbi.nlm.nih.gov/pubmed/28173763
http://dx.doi.org/10.1186/s12879-017-2230-2
_version_ 1782505322251812864
author Aibana, Omowunmi
Bachmaha, Mariya
Krasiuk, Viatcheslav
Rybak, Natasha
Flanigan, Timothy P.
Petrenko, Vasyl
Murray, Megan B.
author_facet Aibana, Omowunmi
Bachmaha, Mariya
Krasiuk, Viatcheslav
Rybak, Natasha
Flanigan, Timothy P.
Petrenko, Vasyl
Murray, Megan B.
author_sort Aibana, Omowunmi
collection PubMed
description BACKGROUND: Ukraine is among ten countries with the highest burden of multidrug- resistant TB (MDR-TB) worldwide. Treatment success rates for MDR-TB in Ukraine remain below global success rates as reported by the World Health Organization. Few studies have evaluated predictors of poor MDR-TB outcomes in Ukraine. METHODS: We conducted a retrospective analysis of patients initiated on MDR-TB treatment in the Kyiv Oblast of Ukraine between January 01, 2012 and March 31st, 2015. We defined good treatment outcomes as cure or completion and categorized poor outcomes among those who died, failed treatment or defaulted. We used logistic regression analyses to identify baseline patient characteristics associated with poor MDR-TB treatment outcomes. RESULTS: Among 360 patients, 65 (18.1%) achieved treatment cure or completion while 131 (36.4%) died, 115 (31.9%) defaulted, and 37 (10.3%) failed treatment. In the multivariate analysis, the strongest baseline predictors of poor outcomes were HIV infection without anti-retroviral therapy (ART) initiation (aOR 10.07; 95% CI 1.20–84.45; p 0.03) and presence of extensively-drug resistant TB (aOR 9.19; 95% CI 1.17–72.06; p 0.03). HIV-positive patients initiated on ART were not at increased risk of poor outcomes (aOR 1.43; 95% CI 0.58–3.54; p 0.44). There was no statistically significant difference in risk of poor outcomes among patients who received baseline molecular testing with Gene Xpert compared to those who were not tested (aOR 1.31; 95% CI 0.63–2.73). CONCLUSIONS: Rigorous compliance with national guidelines recommending prompt initiation of ART among HIV/TB co-infected patients and use of drug susceptibility testing results to construct treatment regimens can have a major impact on improving MDR-TB treatment outcomes in Ukraine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2230-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5294867
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52948672017-02-09 Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine Aibana, Omowunmi Bachmaha, Mariya Krasiuk, Viatcheslav Rybak, Natasha Flanigan, Timothy P. Petrenko, Vasyl Murray, Megan B. BMC Infect Dis Research Article BACKGROUND: Ukraine is among ten countries with the highest burden of multidrug- resistant TB (MDR-TB) worldwide. Treatment success rates for MDR-TB in Ukraine remain below global success rates as reported by the World Health Organization. Few studies have evaluated predictors of poor MDR-TB outcomes in Ukraine. METHODS: We conducted a retrospective analysis of patients initiated on MDR-TB treatment in the Kyiv Oblast of Ukraine between January 01, 2012 and March 31st, 2015. We defined good treatment outcomes as cure or completion and categorized poor outcomes among those who died, failed treatment or defaulted. We used logistic regression analyses to identify baseline patient characteristics associated with poor MDR-TB treatment outcomes. RESULTS: Among 360 patients, 65 (18.1%) achieved treatment cure or completion while 131 (36.4%) died, 115 (31.9%) defaulted, and 37 (10.3%) failed treatment. In the multivariate analysis, the strongest baseline predictors of poor outcomes were HIV infection without anti-retroviral therapy (ART) initiation (aOR 10.07; 95% CI 1.20–84.45; p 0.03) and presence of extensively-drug resistant TB (aOR 9.19; 95% CI 1.17–72.06; p 0.03). HIV-positive patients initiated on ART were not at increased risk of poor outcomes (aOR 1.43; 95% CI 0.58–3.54; p 0.44). There was no statistically significant difference in risk of poor outcomes among patients who received baseline molecular testing with Gene Xpert compared to those who were not tested (aOR 1.31; 95% CI 0.63–2.73). CONCLUSIONS: Rigorous compliance with national guidelines recommending prompt initiation of ART among HIV/TB co-infected patients and use of drug susceptibility testing results to construct treatment regimens can have a major impact on improving MDR-TB treatment outcomes in Ukraine. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-017-2230-2) contains supplementary material, which is available to authorized users. BioMed Central 2017-02-07 /pmc/articles/PMC5294867/ /pubmed/28173763 http://dx.doi.org/10.1186/s12879-017-2230-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Aibana, Omowunmi
Bachmaha, Mariya
Krasiuk, Viatcheslav
Rybak, Natasha
Flanigan, Timothy P.
Petrenko, Vasyl
Murray, Megan B.
Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
title Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
title_full Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
title_fullStr Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
title_full_unstemmed Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
title_short Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine
title_sort risk factors for poor multidrug-resistant tuberculosis treatment outcomes in kyiv oblast, ukraine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294867/
https://www.ncbi.nlm.nih.gov/pubmed/28173763
http://dx.doi.org/10.1186/s12879-017-2230-2
work_keys_str_mv AT aibanaomowunmi riskfactorsforpoormultidrugresistanttuberculosistreatmentoutcomesinkyivoblastukraine
AT bachmahamariya riskfactorsforpoormultidrugresistanttuberculosistreatmentoutcomesinkyivoblastukraine
AT krasiukviatcheslav riskfactorsforpoormultidrugresistanttuberculosistreatmentoutcomesinkyivoblastukraine
AT rybaknatasha riskfactorsforpoormultidrugresistanttuberculosistreatmentoutcomesinkyivoblastukraine
AT flanigantimothyp riskfactorsforpoormultidrugresistanttuberculosistreatmentoutcomesinkyivoblastukraine
AT petrenkovasyl riskfactorsforpoormultidrugresistanttuberculosistreatmentoutcomesinkyivoblastukraine
AT murraymeganb riskfactorsforpoormultidrugresistanttuberculosistreatmentoutcomesinkyivoblastukraine